API maker Tianyin Pharmaceutical warned by NYSE again

By Staff Reporter

- Last updated on GMT

New York Stock Exchange (source: iStock/JaysonPhotography)
New York Stock Exchange (source: iStock/JaysonPhotography)

Related tags Active pharmaceutical ingredients U.s. securities and exchange commission

Tianyin Pharmaceutical failed to file its financial results with the NYSE despite agreeing a compliance plan with the exchange in January.

The US-listed, China-headquartered firm – which makes active pharmaceutical ingredients (APIs), generic drugs and traditional Chinese medicines - announced the warning in a Securities Exchange Commission (SEC) filing yesterday​.

Tianyin explained that it “received a notice from the NYSE MKT Staff indicating that the Company is below certain of the continued listing standards… due to its failure to timely file its Form 10-Q for the period ended December 31, 2015.”

The firm said it “is working to compile and disseminate the information required to be included in the Form 10-Q​.”


Tianyin has received several similar warnings, most recently in October for failing to file reports for the fiscal year ended June 30 and the quarter ended September 30.

It negotiated a compliance plan with the NYSE in January.

Ujnder the plan Tianyin agreed to regain certain unspecified files taken by the Sichuan Province Public Security Department (SPPSD), comply with future filing time lines and “give serious consideration to disclosing estimated figures that reflect its current financial condition​.”

Tianyin did not respond to a request for comment.

The firm manufactures 58 products, including the antibiotic API azithromycin which it makes at a facility in Chengdu, China.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more